
The Society
More than 35,000 clinicians, scientists and allied health professionals from over 160 countries are part of the ERS community
Become an ERS member

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.
The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ...
Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.
Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.
Other cookies are those that are being identified and have not been classified into any category as yet.
EARCO stands for European Alpha-1 Research Collaboration. It is a pan-European network committed to promoting clinical research and education in alpha-1 antitrypsin deficiency (AATD). The core project is the pan-European AATD Registry, a collaboration which will offer longitudinal real-world data for patients with AATD.
EARCO has a global vision to increase the early diagnosis of alpha-1 antitrypsin deficiency (AATD), understand better the natural history of the disease and ensure optimal access to effective care, placing emphasis on ambitions that serve collective needs of the AATD research community and bringing people with AAT deficiency to the centre of the research environment in a real-world context.
The overall goal is to grow to a network of more than 20 countries with 3,000 patients over 3 years.
The aim of the pan-European AATD Registry is to collect prospective, standardised, longitudinal real-world data on a pan-European level in more than 20 countries necessary to understand:
The EARCO Steering Committee is composed of the CRC chairs, clinician researchers, experts in translational research and patient representatives from the Alpha-1 Global network
The Stakeholder Board is composed of a partnership between the different stakeholder groups e.g Steering Committee, National Registry leads, funding partners, scientific experts, and patient advisors.
Bringing together the expertise of all these groups is certain to provide the means to achieve the goals of EARCO.
If you are interested in more information about EARCO or would like to join the registry, please contact scientific@ersnet.org.